FDA approves Lipfendra, the first oral PCSK9 pill for high cholesterol

US regulators have cleared a pill that could reshape how millions of people manage high cholesterol. The Food and Drug Administration has approved Lipfendra, the first oral PCSK9 inhibitor.

PCSK9 inhibitors are powerful cholesterol-lowering drugs that help the liver clear more harmful LDL cholesterol from the blood. Until now the class has been available mainly as injections, which can be a barrier for patients wary of needles or the routine of regular shots.

An oral version removes that barrier. A once-daily pill is generally easier to start, stick with and prescribe than an injectable, which could widen access for people whose cholesterol is not controlled by statins alone — a large group at elevated risk of heart attack and stroke.

Cardiovascular disease remains one of the world's leading causes of death, and lowering LDL cholesterol is one of the best-established ways to reduce that risk. A convenient new tool in that fight has the potential for broad public-health impact.

Lipfendra was not the only notable decision from the agency this month. On July 7, the FDA granted accelerated approval to Trutakna (atacicept) for IgA nephropathy, a progressive kidney disease that had previously offered patients limited treatment options.

Trutakna is described as the first therapy to target two immune-signalling proteins, BAFF and APRIL, at once — an approach researchers hope can slow the disease's advance toward kidney failure.

As with any newly approved medicine, doctors will watch real-world results closely, and patients should make decisions in consultation with their own physicians rather than switching treatments on their own.

Still, the twin approvals point to a productive stretch for a regulator whose decisions ripple through clinics worldwide — and to steady progress against two conditions that affect large numbers of people.